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Aims: Low-density lipoprotein (LDL)-apheresis removes various molecules including LDL/
oxidized LDL and inflammatory cytokines and recovers clinical laboratory parameters. It is
not yet known whether these advantages of LDL-apheresis improve the prognosis of
patients with diabetic nephropathy accompanied by nephrotic syndrome.
Methods: In this study, three groups of patients were retrospectively surveyed in a single
center, and followed for approximately 3 years: an LDL-apheresis cohort (LDL-a; N = 20); a
control cohort meeting the selection criterion of severe proteinuria 3 g/24 h (control-All;
N = 55); and a subgroup of control-All with more severe proteinuria 5 g/24 h (control-mSP;
N = 10), and evaluated the outcomes as survival and renal dysfunction and death/renal
dysfunction free rate.
Results: Death/renal dysfunction free rate was significantly higher in LDL-a than control-All
(x2 = 4.50; P = 0.03) and control-mSP (x2 = 27.68; P < 0.001).
Conclusion: These results suggest the possibilities which LDL-apheresis is considered to
contribute to survival extension and renal function maintenance of severe diabetic ne-
phropathy patients.
# 2014 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under
the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Diabetic nephropathy is the most common cause of end-stage
renal disease (ESRD) [1,2]. The incidence of end-stage kidney
disease requiring chronic hemodialysis caused by diabetic
nephropathy has increased rapidly during the last two decades
worldwide, and morbidity associated with renal dysfunction
involving chronic hemodialysis initiation remains greater than
for those without diabetic nephropathy [3,4]. In the pathogenesis* Correspondence to: Division of Nephrology, Department of Interna
1-380, Matsudo, Chiba Prefecture 270-0034, Japan. Tel.: +81 47 345 111
E-mail address: satou@db4.so-net.ne.jp (E. Sato).
http://dx.doi.org/10.1016/j.diabres.2014.08.012
0168-8227/# 2014 The Authors. Published by Elsevier Ireland Ltd. This
creativecommons.org/licenses/by-nc-nd/3.0/).of diabetic nephropathy, proteinuria, hyperlipidemia, hypergly-
cemia, and hypertension are established risk markers observed
for progressive renal function loss [5–7]. Several clinical trials
have been carried out using drugs such as angiotensin II receptor
blockers (ARB) that improve these markers, and the results
reported that such drugs conferred improvement in proteinuria
and reduction of death and renal dysfunction rates for diabetic
nephropathy with proteinuria [8]. However, there is still
insufficient data concerning prognosis improvement for severe
diabetic nephropathy accompanied by nephrotic syndrome.l Medicine, Shin-Matsudo Central General Hospital, Shin-Matsudo
1; fax: +81 47 343 7363.
 is an open access article under the CC BY-NC-ND license (http://
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protein (LDL)-apheresis is effective in reducing proteinuria
excretion in patients with steroid-resistant nephrotic syn-
drome, focal glomerulosclerosis, and diabetic nephropathy
[9,10]. In addition, LDL-apheresis removes various molecules
such as oxidized LDL and inflammatory cytokines or chemo-
kine and improves clinical laboratory parameters [11–16], and
may reduce renal lesions. We found that LDL-apheresis
reduced excretion of podocytes [17], which have a key role
in maintaining the integrity of the glomerular filtration barrier
[18–20]. These results suggest that the effects of LDL-apheresis
are exerted by removal of oxidative/inflammatory molecules
and modulation of the inflammatory cascade in the glomeru-
lus, and that it is a potentially effective treatment for diabetic
nephropathy with severe proteinuria [17]. It is unknown
whether these advantages of LDL-apheresis improve progno-
sis in terms of mortality or renal dysfunction. The purpose of
the present study is to estimate, by means of a retrospective
review, the prognosis of diabetic nephropathy with severe
proteinuria treated with LDL-apheresis therapy.
1.1. Subjects
The present study is a single-center, retrospective review of
diabetic nephropathy patients, consisting of an LDL-apheresis
cohort and a control cohort with one subgroup. The LDL-
apheresis cohort (LDL-a) is composed of all patients who
underwent LDL-apheresis therapy at Shin-Matsudo Central
General Hospital, Chiba, Japan prior to 2010 (N = 20). The
control cohort is composed of all patients at the same hospital
who met the inclusion criteria of severe proteinuria 3 g/24 h
from 2008 to 2010 and who were traceable (control-All; N = 55);
a subgroup of the control cohort comprises the patients in
control-All with severe proteinuria 5 g/24 h (control-mSP;
N = 10) near to that of LDL-a.
2. Methods
2.1. Diagnosis criteria of diabetic nephropathy
Diabetic nephropathy was diagnosed based on the presence of
following diabetic lesions: glomerulosclerosis such as nodular
or diffuse (mesangial expansion), hyalinization of the renal
arterioles, linear deposits of IgG in the glomerular basement
membrane, and diffuse thickening of the glomerular base-
ment on electron microscopy. If there is no renal biopsy data of
diabetic lesions, as a substitute by evaluation of clinical
laboratory tests: clinical syndrome characterized by persistent
albuminuria (>300 mg/24 h) (also referred to as macroalubu-
minuria or proteinuria), a steady decline in glomerular
filtration rate (GFR), and elevated blood pressure [21].
2.2. Clinical parameters and laboratory measurements
Body mass index was calculated as body weight (in kilograms)
divided by height (in meters) squared. Hypertension was defined
according to WHO criteria (systolic blood pressure [BP] >
160 mmHg and/or diastolic BP > 95 mmHg, or on antihyperten-
sive treatment at baseline). Hypercholesterolemia was definedaccording to the criteria total cholesterol >220 mg/dL and LDL-
cholesterol >140 mg/dL. Stroke was defined as a reported
medical history of cerebral infarction or cerebral hemorrhage.
Coronary artery disease (CAD) was defined as a reported history
of myocardial infarction, angina, percutaneous coronary inter-
vention, or coronary artery bypass graft. Retinopathy and
neuropathy were determined from the reported medical history.
Samples of blood and urine taken at routine clinical
checkups were analyzed at baseline for creatinine, total
protein, LDL-cholesterol, and HbA1c and for protein and
liver-type fatty acid binding protein (L-FABP), respectively.
2.3. Outcomes assessment
Baseline for LDL-a and the control cohorts is defined as the day
of starting LDL-apheresis therapy or meeting the inclusion
criteria, respectively. Surveillance for major events included
screening hospitalization history until 3 years from baseline.
A major event was defined as any incident of stroke, CAD,
renal dysfunction, or death. Renal dysfunction was defined as
doubling of serum creatinine concentration, chronic hemodi-
alysis initiation, or renal transplantation [8]. Doubling of
serum creatinine concentration was defined as the first serum
creatinine concentration that was twice the baseline, as
confirmed by a second serum creatinine concentration
obtained at about 3 months after the initial doubling.
2.4. LDL-apheresis
LDL-apheresis was performed using hollow polysulfone fibers
(Sulflux; Kaneka Co. Ltd., Osaka, Japan) as the plasma separator
and a dextran sulfate cellulose column (Liposorber; Kaneka Co.
Ltd., Osaka, Japan) as the LDL absorber. About 3000 to 4000 mL of
plasma (60 mL/kg body weight) was treated for 3 h in each
apheresis session [9]. LDL-apheresis was performed in series
twice a week for 3–6 weeks (6–12 times per patient).
2.5. Statistical analysis
Data are expressed as the mean  SD. Differences in baseline
characteristics between two cohorts were evaluated by the chi-
square test, or Fisher’s exact test for categorical variables or
Student’s t test for continuous variables. Survival, major event
free, renal dysfunction free, and death/renal dysfunction free
rates for the cohorts were estimated by the Kaplan–Meier
method and analyzed by log-rank tests [22]. Prognostic factors
of severe diabetic nephropathy were estimated by logistic
regression analysis. Statistical analyses were performed using
SPSS version 16.0.
3. Results
3.1. Characteristics of each cohort
Baseline characteristics of LDL-a and the control cohorts
are listed in Table 1. Disease severity parameters such as
eGFR (35.1  17.7 mL/min/1.73 m2 vs. 48.6  26.6 mL/min/
1.73 m2; P = 0.04), total protein (3.9  0.3 g/dL vs. 6.7  0.7
g/dL; P < 0.001), LDL cholesterol (227.1  33.0 mg/dL vs.
Table 1 – Baseline characteristics.
LDL-a Control
(N = 20) All (N = 55) P Value mSP (N = 10) P Value
Male/female 15/5 35/20 0.4 5/5 0.2
Age (years) 59.3  13.8 65.9  12.1 0.05 62.4  14.1 0.6
Diabetes duration (years) 21.3  10.0 14.0  8.5 0.004 17.7  13.8 0.5
Follow-up (years) 2.7  0.4 2.5  0.7 0.2 2.8  0.4 0.6
BMI (kg/m2) 26.9  3.4 24.4  4.4 0.03 25.3  5.5 0.4
Serum creatinine (mol/L) 170.6  81.3 142.3  126.4 0.4 198.0  155.6 0.5
eGFR (mL/min/1.73 m2) 35.1  17.7 48.6  26.6 0.04 36.7  32.2 0.9
Total protein (g/dL) 3.9  0.3 6.7  0.7 <0.001 6.3  0.8 <0.001
LDL-cholesterol (mg/dL) 227.1  33.0 157.1  69.1 <0.001 165.8  61.8 0.002
HbA1c (%) 7.6  0.8 7.4  2.0 0.7 6.8  2.3 0.2
Proteinuria (g/24 h) 10.5  2.1 3.7  1.9 <0.001 6.8  2.9 <0.001
L-FABP (urinary, mg/gCr) 179.1  84.0 100.5  57.1 <0.001 129.9  64.7 0.1
Stroke (history; n, %) 12, 60 14, 25 <0.001 3, 30 0.1
CAD (history; n, %) 14, 70 9, 16 <0.001 4, 40 0.1
Hypertension (n, %) 14, 70 42, 76 0.6 9, 90 0.2
Hypercholesterolemia (n, %) 20, 100 33, 60 0.03 9, 90 0.3
Retinopathy (n, %) 15, 75 33, 60 0.2 7, 70 0.6
Neuropathy (n, %) 15, 75 15, 27 <0.001 3, 30 0.02
Heart failure (n, %) 14, 70 9, 16 <0.001 5, 50 0.3
ACE inhibitor (n, %) 3, 15 8, 15 0.6 2, 20 0.8
ARB (n, %) 14, 70 27, 49 0.1 6, 60 0.4
Statin (n, %) 20, 100 18, 33 <0.001 6, 60 0.008
Insulin (n, %) 8, 40 11, 20 0.08 2, 20 0.3
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3.7  1.9 g/24 h; P < 0.001), and L-FABP (179.1  84.0 mg/gCr vs.
100.5  57.1 mg/gCr; P < 0.001) were significantly more severe in
LDL-a than control-All; however, there was no difference in
serum creatinine (170.6  81.3 mol/L vs. 142.3  126.4 mol/L;
P = 0.35). Total protein (6.3  0.8 g/dL; P < 0.001), LDL cholesterol
(165.8  61.8 mg/dL; P = 0.002), and proteinuria (6.8  2.9 g/24 h,
P < 0.001) were significantly more severe in LDL-a than control-
mSP. In LDL-a cohort, LDL cholesterol levels were significantly
decreased after LDL-apheresis treatment (from base line:
227.1  33.0 mg/dL to after: 88.0  15.5 mg/dL; P < 0.001) and
restored to normal range.
Life-threatening history or concomitant diseases such as
stroke (P < 0.001), coronary artery disease (CAD; P < 0.001), and
heart failure (P < 0.001) were significantly higher in LDL-a thanTable 2 – List of major events.
LDL-a Control
(N = 20) All (N =
Stroke (n, %) 5 (25) 6 
CAD (n, %) 11 (55) 10 
Renal dysfunction (n, %) 5 (25) 23 
Creatinine doubling (n, %) 5 (25) 19 
Dialysis initiation (n, %) 5 (25) 16 
Death (n, %) 1 (5) 15 
<Cause of death>
Stroke 2
AMI 1 1
Heart failure 6 
Renal failure 2
Infection 1 
Other 3 
Event-free (n, %) 6 (30) 20 control-All; however, there were no differences in life-
threatening history or concomitant diseases between LDL-a
and control-mSP.
The frequency of use of anti-hypertension drugs, ACE
inhibitors and ARB, and insulin were almost the same in each
cohort. On the other hand, the frequency of statin use was
significantly higher in LDL-a (100%) than control-All (33%;
P < 0.001) and control-mSP (60%; P = 0.008).
3.2. Major events
Major events for LDL-a and the control cohorts are listed in
Table 2. Major events were observed for 14 patients (70%) in
LDL-a, 35 patients (64%) in control-All, and 10 patients (100%)
in control-mSP. Incidence of CAD was significantly higher in 55) P value mSP (N = 10) P value
(11) 0.1 2 (20) 0.6
(18) 0.002 2 (20) 0.07
(42) 0.18 10 (100) <0.001
(35) 0.4 9 (90) 0.001
(29) 0.7 8 (80) 0.006
(27) 0.03 3 (30) 0.1
1
1
1
(36) 0.61 0 (0) 0.07
Fig. 2 – Renal dysfunction free rates estimated by Kaplan–
Meier analysis and analyzed by log-rank tests. Black line
denotes LDL-a (N = 20), gray line denotes control-All (all,
N = 55), and dashed-gray line denotes the cohort with
more severe proteinuria, control-mSP (N = 10). Renal
dysfunction free rate was significantly higher in LDL-a
than control-mSP (x2 = 28.4; P < 0.001).
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higher (P = 0.03) in control-All (N = 15; 27%) than LDL-a (N = 1;
5%). The most common cause of death in control-All was heart
failure, followed by stroke and renal failure. In the renal
dysfunction component, incidence of serum creatinine dou-
bling and chronic hemodialysis initiation were significantly
higher in control-All than in LDL-a (P = 0.001 and P = 0.006,
respectively).
3.3. Outcome Analysis
Survival, renal dysfunction free, death/renal dysfunction free,
and major event free rates were estimated by the Kaplan–
Meier method and analyzed by log-rank tests. The survival
rate was significantly higher in LDL-a than control-All
(x2 = 4.05 [P = 0.04] vs. x2 = 2.72 [P = 0.1] at 2 years follow-up)
(Fig. 1); however, there was no significant difference compared
with control-mSP (x2 = 2.83; P = 0.09) (Fig. 1). The renal
dysfunction free rate was significantly higher in LDL-a than
control-mSP (x2 = 28.4 [P < 0.001] vs. x2 = 30.5 [P < 0.001] at 2
years follow-up) (Fig. 2). There was no significant difference
between LDL-a and control-All (x2 = 3.00; P = 0.08), but a
difference was observed at 2 years follow-up (x2 = 7.26;
P = 0.007). The death/renal dysfunction free rate was also
significantly higher in LDL-a than control-All (x2 = 4.50
[P = 0.03] vs. x2 = 6.91 [P = 0.009] at 2 years follow-up); further-
more, there was a significant difference between LDL-a and
control-mSP (x2 = 28.02 [P < 0.001] vs. x2 = 27.68 [P < 0.001] at 2
years follow-up) (Fig. 3). On the other hand, the major event
free rate showed no significant difference between LDL-a and
control-All (x2 = 0.43; P = 0.5) (figure not shown).
To estimate the independent prognostic factors of severe
diabetic nephropathy, baseline variables were compared for
death, renal dysfunction, and death/renal dysfunction in
control-All. Age, BMI, serum creatinine, total protein, and
LDL-cholesterol were identified as candidates, and LDL-choles-
terol was finally estimated by multiple logistic regression
analysis as the common independent prognostic factor for
death (OR, 0.96; 95% CI [0.93–1.00]; P = 0.03), renal dysfunctionFig. 1 – Survival rates estimated by Kaplan–Meier analysis
and analyzed by log-rank tests. Black line denotes LDL-a
(N = 20) and gray line denotes control-All (all; N = 55), and
dashed-gray line denotes the cohort with more severe
proteinuria, control-mSP (N = 10). Survival rate was
significantly higher (x2 = 4.05; P = 0.04) in LDL-a than
control-All.(OR, 0.93; 95% CI [0.88–0.99]; P = 0.03), and death/renal dysfunc-
tion (OR, 0.94; 95% CI [0.88–1.00]; P = 0.04) (Table 3). In addition,
total protein was also an independent prognostic factor for
death/renal dysfunction (OR, 50.0; 95% CI [2.52–989.8]; P = 0.01).
In order to examine the influence for the prognosis of statins
having an LDL-cholesterol lowering effect, control-All was
divided into two groups of patients who met the respective
inclusion criteria of with or without the initiation of statin
therapy, and survival and death/renal dysfunction free rates
were estimated by the Kaplan–Meier method and analyzed by
log-rank tests. Statin therapy was initiated for 18 patients and
not initiated for 37. There were no significant differences
between the groups with or without the initiation of statin
therapy in terms of the survival rate (x2 = 0.11; P = 0.7), renal
dysfunction free rate (x2 = 0.19; P = 0.7), or death/renal dysfunc-
tion free rate (x2 = 0.31; P = 0.6) (figure not shown).Fig. 3 – Death/renal dysfunction free rates estimated by
Kaplan–Meier analysis and analyzed by log-rank tests.
Black line denotes LDL-a (N = 20), gray line denotes
control-All (all; N = 55), and dashed-gray line denotes the
cohort with more severe proteinuria, control-mSP (N = 10).
Death/renal dysfunction free rate was significantly higher
in LDL-a than control-All (x2 = 4.50; P = 0.03) and control-
mSP (x2 = 28.02; P < 0.001).
Table 3 – Prognostic factors of severe diabetic nephropathy analyzing control-All cohort.
Variable Death Renal dysfunction Death/renal dysfunction
OR 95% CI P value OR 95% CI P value OR 95% CI P value
Age 0.86 0.74–1.01 0.06
BMI 1.35 0.89–2.04 0.1
Creatinine
(serum)
0.97 0.95–1.00 0.06
Total protein
(serum)
6.55 0.51–84.70 0.15 50.0 2.52–989.8 0.01
LDL-cholesterol 0.96 0.93–1.00 0.03 0.93 0.88–0.99 0.03 0.94 0.88–1.00 0.04
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Diabetic nephropathy is a potentially life-threatening condi-
tion having a poor prognosis, with a high risk of progression to
end-stage renal failure. Although there have been several
reports noting short-term recovery of clinical symptoms or
parameters with LDL-apheresis therapy, there is insufficient
data or evidence about its long-term effects, such as its
prognostic effect. In this retrospective study, we followed up
patients with severe diabetic nephropathy in the LDL-a
and control cohorts and examined the long-term effects of
LDL-apheresis.
According to the baseline characteristics and medical
history, the disease condition of LDL-a was more severe than
control-All, and the condition of control-mSP was more severe
than control-All and near that of LDL-a but not at the same level.
Despite the difference in the degree of disease severity, survival
and the renal dysfunction free and death/renal dysfunction free
rates were significantly higher in LDL-a than the control
cohorts. Furthermore, LDL-a cohort compared with Reduction
in End Points in Noninsulin-Dependent Diabetes Mellitus with
the Angiotensin II Antagonist Losartan (RENAAL) study sub-
group data (albuminuria >3.0 g/g subgroup; 289 patients) [7].
Baseline data were similar with LDL-a cohort in this study (age:
58.1  7.8 vs. 59.3  13.8, serum creatinine: 2.1  0.5 mg/dL vs.
1.9  0.9 mg/dL as described 170.6  81.3 mol/L in manuscript,
eGFR: 33.8  11.0 mL/min/1.73 m2 vs. 35.1  17.7 mL/min/
1.73 m2, proteinuria: 8.9  4.3 g/day vs. 10.5  2.1 g/day; albu-
minuria >3.0 g/g subgroup vs. LDL-a cohort, respectively). On
the other hand, obvious difference was observed in the
prognosis of these cohorts. The death/renal dysfunction
(defined as doubling of serum creatinine concentration, chronic
hemodialysis initiation, or renal transplantation) rate were
probably 60% in albuminuria >3.0 g/g subgroup and 5% in LDL-a
cohort for 2 years, and probably 80% in albuminuria >3.0 g/g
subgroup and 30% in LDL-a cohort for 3 years, respectively.
LDL-a cohort was small, but this comparison result was very
impressive and suggested the possibility of LDL apheresis
therapy for severe diabetic nephropathy patients.
A survey of the prognostic factors identified LDL-
cholesterol as an estimated common independent factor for
diabetic nephropathy with severe proteinuria. Furthermore,
despite the fact that statin also reduces the serum LDL-
cholesterol level, statin administration had no influence on
the prognosis. LDL-apheresis is considered to directly focus on
the therapeutic target LDL-cholesterol, and may be a promis-
ing therapy for diabetic nephropathy with severe proteinuria.On the other hand, although the survival rate was significantly
different between LDL-a and control-All, there was no
significant difference from the more severe cohort, control-
mSP, as noted above. Similarly, despite the fact that LDL-
apheresis therapy reduces serum LDL-cholesterol, which is
one of the risks for CAD, the incidence of CAD was higher in
LDL-a than control-All. These trends are thought to be due to
the small size of the LDL-a and control-mSP cohorts. However,
statistical analysis confirmed the possibilities which LDL-
apheresis contributes to improvement in avoiding death and
renal dysfunction in severe diabetic nephropathy patients in
the nephrotic syndrome state.
In the pathogenesis of diabetic nephropathy, proteinuria is
one of the established risk markers observed for progressive
renal function loss [5,6]. Renal function loss is exacerbated by
collapse of the glomerular filtration barrier structure. Podo-
cytes, which have a key role in maintaining the integrity of the
glomerular filtration barrier, are also a clinically effective
marker and linked to the development of proteinuria [9,11,12].
We previously reported that LDL-apheresis effectively reduces
podocyte excretion and ameliorates renal dysfunction in
patients with nephrotic syndrome caused by diabetic ne-
phropathy, and suggested the possibility that LDL-apheresis
maintains renal function by protecting podocytes [17]. Some
investigators have reported a relationship between hyper
LDL-cholesterolemia and glomerular injury in inflammation
[23,24]. With oxidative modifications of the major cholesterol-
carrying lipoproteins, the LDLs, the oxidized LDLs are taken up
by the scavenger receptor of macrophages, which leads to the
formation of foam cells and thrombus, and stimulates
monocytes to secrete various cytokines, thus accelerating
inflammation [11]. According to the results of several studies
showing that LDL-apheresis removes various molecules such
as oxidized LDL, TNF-alfa, IL-6, VEGF, and MCP-1, among the
inflammatory cytokines or chemokines [16], the clinical
efficacy of LDL-apheresis is considered to be exerted by the
removal of oxidative/inflammatory molecules and modula-
tion of the inflammatory cascade in the glomerulus. There-
fore, LDL-apheresis is a promising therapy that rescues renal
function by maintenance of the glomerular basement mem-
brane/podocytes, and contributes to improving the prognosis
of diabetic nephropathy with severe proteinuria.
In this study, all patients in the LDL-a cohort received only
one course of six to 12 sessions of LDL-apheresis therapy, and
drug medication such as statin, ARB, and insulin for diabetic
nephropathy were started or continued. Renal function
maintenance was higher in LDL-a compared with the control
cohorts, and LDL-apheresis therapy actually delayed the
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 0 6 ( 2 0 1 4 ) 2 4 1 – 2 4 6246progression of ESRD or initiation of chronic hemodialysis.
However, although the renal function maintenance rate
remained high until approximately day 900 after LDL-apheresis,
the rate then fell slightly in LDL-a. These processes may suggest
that LDL-apheresis is a therapy that should be considered not
only once, but twice or more times, adjusting the treatment to
the patient’s condition.
In this study, we found the possibilities which LDL-apheresis
contributes to survival extension and renal function mainte-
nance in severe diabetic nephropathy patients. However, this
study has some limitations such as retrospective design and
performed in one hospital, we think it is not enough as evidence.
In the future, a prospective study will be carried out, and we
expect to accumulate more evidence to establish the most
suitable therapy.
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